阅读说明：本技术 用于治疗肿瘤的分次放射与sapc-dops的组合疗法 (Combination therapy of fractionated radiation with SAPC-DOPS for the treatment of tumors ) 是由 X·齐 H·W·戴维斯 于 2018-10-16 设计创作，主要内容包括：提供了治疗有需要的患者的恶性实体瘤的方法,该方法包括向患者施用组合疗法,所述组合疗法包括：分次放射疗法和治疗有效量的鞘脂激活蛋白C(SapC)和二油酰基磷脂酰丝氨酸(SapC-DOPS),其中分次放射疗法包括多个放射部分,每个所述部分所递送的辐射剂量低于单独施用时有效抑制肿瘤生长的剂量。还提供了增强SapC-DOPS的抗肿瘤功效的方法。(There is provided a method of treating a malignant solid tumor in a patient in need thereof, the method comprising administering to the patient a combination therapy comprising: fractionated radiation therapy and therapeutically effective amounts of sphingolipid activating protein C (SapC) and dioleoylphosphatidylserine (SapC-DOPS), wherein the fractionated radiation therapy comprises a plurality of fractions of radiation, each of said fractions delivering a dose of radiation that is less than the dose effective to inhibit tumor growth when administered alone. Also provided are methods of enhancing the anti-tumor efficacy of SapC-DOPS.)

1. A method of treating a malignant solid tumor in a patient in need thereof, the method comprising administering to the patient a combination therapy comprising:

fractionated radiation therapy, wherein fractionated radiation therapy comprises a plurality of radiation fractions, each of said fractions delivering a radiation dose that is less than the dose effective to inhibit tumor growth when administered alone; and

a therapeutically effective amount of sphingolipid activator protein C and dioleoylphosphatidylserine (SapC-DOPS).

2. The method of claim 1 wherein fractionated radiation therapy comprises from about 20 to about 40 fractions.

3. The method of claim 1, wherein SapC-DOPS is administered in multiple doses over a treatment period.

4. The method of claim 3, wherein the treatment period comprises a continuous period of about 20 to about 40 days.

5. The method of claim 3 wherein the plurality of doses of SapC-DOPS comprise about 10 to about 20 doses over the treatment period.

6. The method of claim 3 wherein the dose of SapC-DOPS comprises from about 0.3mg/kg to about 1.2 mg/kg.

7. The method of claim 1, wherein fractionated radiation therapy comprises a total radiation dose of about 20Gy to about 80 Gy.

8. The method of claim 1, wherein each fraction comprises a radiation dose of about 1Gy to about 2 Gy.

9. The method of claim 1 wherein one or more fractions are administered prior to administration of SapC-DOPS.

10. The method of claim 1 wherein one or more fractions are administered after administration of one or more doses of SapC-DOPS.

11. The method of claim 1, wherein one or more portions are administered simultaneously with SapC-DOPS.

12. The method of claim 1, wherein the malignant solid tumor is a brain, pancreas, lung, appendix, or neuroblastoma tumor.

13. The method of claim 1, wherein SapC-DOPS is administered by intravenous route.

14. The method of claim 1, wherein 10-15 doses of SapC-DOPS are administered over a 28 day treatment period.

15. A method of enhancing the anti-tumor efficacy of SapC-DOPS in a subject having a malignant solid tumor, the method comprising:

administering to the subject a therapeutically effective amount of SapC-DOPS in combination with fractionated radiation therapy, wherein the fractionated radiation therapy comprises a plurality of fractions of radiation administered over a treatment period, each of said fractions delivering a radiation dose that is lower than the dose effective to inhibit tumor growth when administered alone, wherein the fractionated radiation therapy enhances the anti-tumor efficacy of SapC-DOPS.

16. The method of claim 15, wherein the malignant solid tumor is a brain, pancreas, lung, or neuroblastoma tumor.

17. The method of claim 15, wherein SapC-DOPS and the radioactive moiety are administered simultaneously or sequentially.

18. The method of claim 15, wherein the treatment period comprises a continuous period of about 20 to about 40 days.

19. The method of claim 15, wherein SapC-DOPS is administered in multiple doses over a treatment period, wherein each of the doses comprises from about 0.3mg/kg SapC to about 1.2mg/kg SapC.

20. The method of claim 15, wherein fractionated radiation therapy comprises a total radiation dose of about 20Gy to about 80Gy, and wherein each fraction comprises a radiation dose of about 1Gy to about 5 Gy.

Technical Field

The present disclosure relates to the field of anti-cancer therapy, and more particularly to methods for treating tumors.

Background

Glioblastoma is the most common primary CNS malignancy in adults and accounts for nearly 75% of cases. Despite steady progress in its treatment due to improvements in neuroimaging, microsurgery and radiation, glioblastoma remains incurable. Glioblastomas die due to rapid, aggressive and invasive growth in the brain. Glioblastoma is also relatively resistant to radiation and chemotherapy, and therefore the recurrence rate after treatment is high. Furthermore, the immune response to tumor cells is largely ineffective in completely eliminating residual tumor cells after resection and radiation therapy.

Normal living cells predominantly display Phosphatidylserine (PS) in the intracellular leaflet of the plasma membrane. In contrast, even in certain types of cancer, viable cancer cells have high levels of PS on the outer surface and exhibit extensive surface PS. Active agents targeting surface PS have recently been developed to treat tumors and are expected to be more effective at higher surface PS levels.

Phospholipids are asymmetrically arranged in the cell membrane with neutral phospholipids on the outer leaflet, while anionic phospholipids (e.g. Phosphatidylserine (PS) and phosphatidylethanolamine) are mainly located inside the membrane. The early event of apoptosis is the presence of Phosphatidylserine (PS) on the cell surface. The PS reminds phagocytes the phagocyte to develope the cell, thereby reducing the inflammatory response. External PS elevation is also found in non-apoptotic primary and metastatic cancer cells and their associated tumor vasculature. In addition, surviving cancer cells with high external PS are resistant to phagocyte-mediated removal. Macrophages recognize PS on the surface of apoptotic cells, but cancer cells apparently inhibit macrophages by displaying CD47, thereby inhibiting phagocytosis. Recent studies have shown that this superficial PS can be used as an important target for cancer therapy.

The loss of PS asymmetry in cancer cells may be due to decreased ATP-dependent phospholipid translocase (flippase) activity and/or increased phospholipid reptiliase activity, possibly associated with intracellular calcium (Ca)²⁺ _i) The level is high. Although cancer cells usually have a higher amount of PS on the surface, their content varies greatly in cultured cell lines even in the same type of cancer. Cancer cells with high external PS have reduced flippase activity and high (Ca) compared to cancer cells with lower surface PS²⁺ _i). High surface PS cells also have elevated total cellular PS. Importantly, this increased PS is inducible and is not associated with programmed cell death.

Radiotherapy is a common therapy for malignancies and has been shown to improve prognosis when used with chemotherapy. However, radiation may damage the target tissue, and there is evidence that radiation may promote tumor growth by stimulating angiogenesis and cancer cell migration. Interestingly, irradiation increased the surface PS on tumor vessels, and the antibody baviximab targeting PS has been successfully used in mouse models of lung cancer and glioblastoma.

There is a continuing need for improved cancer therapies.

SUMMARY

Since SapC-DOPS performs better in high surface PS cells, selection of high surface PS cells by irradiation can reduce the effects of subsequent irradiation and even chemotherapy, but will enhance sensitivity to SapC-DOPS treatment, thereby introducing an effective new combination therapy.

The following summary of the disclosure is provided to facilitate an understanding of some of the innovative features unique to the present disclosure and is not intended to be a full description. A full appreciation of the various aspects of the invention can be gained by taking the entire specification, claims, drawings, and abstract as a whole.

In one embodiment, there is provided a method of treating a malignant solid tumor in a patient in need thereof, the method comprising administering to the patient a combination therapy comprising: fractionated radiation therapy and a therapeutically effective amount of sphingolipid activating protein (saposin) C and dioleoylphosphatidylserine (SapC-DOPS), wherein the fractionated radiation therapy comprises a plurality of radiation fractions each of which delivers a radiation dose that is less than the dose effective to inhibit tumor growth when administered alone.

In another embodiment, there is provided a method of enhancing the anti-tumor efficacy of SapC-DOPS in a subject having a malignant solid tumor, the method comprising: administering to a subject a therapeutically effective amount of SapC-DOPS in combination with fractionated radiation therapy, wherein fractionated radiation therapy comprises a plurality of fractions of radiation administered over a treatment period, each of said fractions delivering a radiation dose that is less than the dose effective to inhibit tumor growth when administered alone, wherein fractionated radiation therapy enhances the anti-tumor efficacy of SapC-DOPS.

Brief Description of Drawings

FIGS. 1A-C) cfPac-1 cells (a human pancreatic cancer cell line) were irradiated at 0, 2, 6, 10 and 16 Gy. After 24hr, annexin V-FITC staining was performed and cells were treated by flow cytometry. A) And (4) carrying out cell gating. And (3) FSC: forward light scattering, indicative of cell volume; SSC: lateral light scattering, indicating cell granularity. B) And (4) gating live cells. PI (propidium iodide) only stains dead cells. C) Histograms of cells stained with annexin V-FITC show the effect of increasing doses of radiation on annexin V staining (i.e. surface PS). D-H) cells were irradiated at the doses indicated and annexin V-FITC staining was determined after 24hr on low surface PS cells (less than 2000 fluorescence units, D) or medium or high surface PS cells (greater than 3000 fluorescence units, E). F) Cells were irradiated at 5Gy and analyzed at the indicated times (A2058, cfPac-1 and U87 MG). To examine whether the tumor cell surface PS was also increased by irradiation, 2x10 was used⁶cfPac-1(G) or NCI-H460(H) cells were injected subcutaneously into nude mice. When the tumor is 400mm³In time, some tumors were treated with 10Gy of directed irradiation as described in the examples section. Tumors were excised 48hr later, and then cells were scattered into single cells. Cells in all groups were then treated and gated as shown in figure 1. P<0.05，**p<0.01. cfPac-1 and PANC-1 are pancreatic cancer cell lines; a2058 is a melanoma cell line; NCI-H460 and H1915 are metastatic lungsA cancer cell line; u87MG is a glioblastoma cell line, HPDE is a normal, immortalized pancreatic cell line, and HUVEC is primary human umbilical vein endothelial cells.

Figure 2 shows cfPac-1 cells irradiated at 10Gy in the presence or absence of 10 μ M Z-VAD-fmk, Sigma (St. L ouis, MO), 24hr later, cells were evaluated for annexin V binding p <0.01, NS-no significant difference from control as shown in figure 1.

FIG. 3 shows determination of surface PS from untreated cells by annexin V-FITC staining and cell viability by MTT assay. Each point represents the average of two measurements. R was calculated using GraphPad Prism 6 software²And a p value. A) Shows the results for 2 Gy; B) shows the results for 6 Gy); C) shows the results for 10 Gy; and D) shows the result at 16 Gy.

FIG. 4 cells were irradiated at 10Gy and SapC-DOPS was added for 24 hours. Cell death was analyzed 72hr later using the MTT assay. The concentration of SapC-DOPS was 25. mu.M for A2058, cfPac-1 and PANC-1, and 40. mu.M for U87 MG. Shown is the% viable cells of each cell line compared to the control (no irradiation, no SapC-DOPS). P <0.05, p <0.01, NS-no significant difference compared to control. A) Results for a2058 cells are shown; B) shows the results for cfPac-1 cells; C) results for U87MG cells are shown; and D) shows the results for PANC-1 cells.

FIG. 5 shows the results of treatment of the A2058, cfPac-1 and U87MG cell lines irradiated at 5Gy per week for different weeks (Rx denotes the number of weeks of irradiated cells). Cells that were not irradiated continuously were designated as R0. The medium was changed immediately after irradiation and the cells were allowed to divide every 3-4 days. Treatment was given for 4-7 days after the last 5Gy irradiation while the surface PS was still elevated. A) Schedule of treatment regimen. B) Surface PS was determined by annexin V-FITC staining on day 4 after the last 5Gy irradiation. Rx; for a2058, x is 15; for cfPac-1 and U87MG, x is 10. Compared with R0<0.05，**p<0.01. Mean and s.d. C-E) cells were irradiated continuously with 5 Gy. (upper panel, A2058 cells; middle panel, cfPac-1 cells; lower panel, U87MG cells). C) After 7 days, they were exposed to the indicated doses of radiation and after 72hr were determined by MTTThe method is used for measuring the cell viability. Shown is the percentage of viable cells, 100% of which served as a normalization control for each cell line. Compared with R0<0.05，**p<0.01. D) Cells were treated with different doses of Gemcitabine (GEM) Temozolomide (TMZ) or cisplatin 7 days after the last 5Gy irradiation, and cell viability was determined by MTT assay after 72 hrs. Compared with the R0 of the same dose of medicine,^#p<0.05，^##p<0.01. E) 7 days after the last 5Gy irradiation, cells were treated with SapC-DOPS (1SapC:7DOPS, Mol: Mol) at the indicated dose, and cell viability was determined by MTT assay after 72 hr. The concentration of SapC-DOPS was 25. mu.M for A2058, cfPac-1 and PANC-1, and 40. mu.M for U87 MG. Shown are% of viable cells, 100% of which served as normalization controls for each cell line (as well as R0 and Rx). P<0.05，**p<0.01, NS is not significantly different.

FIG. 6 shows combination therapy of radiation with SapC-DOPS versus injection of 1X10⁶Results of mice with NCI-H460 cells. When the tumor reaches-100 mm³Mice were irradiated with 10Gy on days 9 and 16 after cell injection. SapC-DOPS (4mg/kg) was injected by tail vein injection on days 11, 14, 15, 16, 17 and 18. Mice were euthanized on day 22 and tumors were excised, washed with saline and weighed. The p-values from the t-test are shown.

FIG. 7 depicts the structure of SapC-DOPS.

Sequence listing

The CRF Sequence table with filename 10738 and 681_ Sequence _ L existing.txt created on day 10, 15 of 2018, filed by applicant herein incorporated by reference.

The standard letter abbreviations for the nucleotide bases as defined in 37c.f.r.1.822 are used to represent the nucleic acid and amino acid sequences listed in the accompanying sequence listing. Each nucleic acid sequence shows only one strand, but the complementary strand is understood to be encompassed by the contents of any reference displayed strand.

In the accompanying sequence listing:

SEQ ID NO. 1 shows the peptide sequence of sphingolipid activating protein C.

Detailed Description

The following description of specific embodiments is merely exemplary in nature and is in no way intended to limit the scope, application, or uses of the invention, which can, of course, vary. The invention is described using non-limiting definitions and terminology included herein. These definitions and terminology are not intended to limit the scope or practice of the present invention but are presented for exemplary and descriptive purposes only.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms "a", "an" and "the" are intended to include the plural forms as well, including "at least one", unless the context clearly indicates otherwise. "or" means "and/or". As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items. It will be further understood that the terms "comprises" and/or "comprising," or "includes" and/or "including," when used in this specification, specify the presence of stated features, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and/or groups thereof. The term "or a combination thereof" refers to a combination comprising at least one of the foregoing elements.

Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the presently disclosed subject matter.

As used herein, the term "about" when referring to a value or amount of mass, weight, time, volume, pH, size, concentration, or percentage is intended to encompass variations of in some embodiments ± 20%, in some embodiments ± 10%, in some embodiments ± 5%, in some embodiments ± 1%, in some embodiments ± 0.5%, in some embodiments ± 0.1% relative to the specified amount, as such variations are suitable for practicing the disclosed methods.

It should be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitations were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that falls within such broader numerical range, as if such narrower numerical ranges were all expressly written herein.

Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

As used herein, "malignant solid tumor" refers to an abnormal mass of cancer cells, which typically does not contain cysts or fluid regions. In embodiments, the solid tumor is a brain, pancreas, lung, appendix, or neuroblastoma tumor. In some embodiments, the tumor is a brain tumor, such as a glioblastoma. As used herein, "glioblastoma multiforme", "GBM" and "glioblastoma multiforme" refer to grade IV primary glioma brain cancer.

As used herein, "subject" or "patient" refers to a mammal. Optionally, the subject or patient is a human or non-human primate. Optionally, the subject or patient is a dog, cat, horse, sheep, cow, rabbit, pig or mouse.

The term "sequentially" as used herein refers to a treatment regimen wherein a first therapeutic agent or therapy is administered followed by administration of a second therapeutic agent or therapy. In an embodiment, the therapy comprises radiation therapy, including a radiation moiety.

The term "concurrently" as used herein refers to administration of a first therapeutic agent or therapy and administration of a second therapeutic agent or therapy, wherein the first and second therapeutic agents or therapies are separate and administered substantially simultaneously. In an embodiment, the therapy comprises radiation therapy, including a radiation moiety.

As used herein, the term "pharmaceutically acceptable excipient" refers to any physiologically inert, pharmacologically inert material known to those skilled in the art that is compatible with the physical and chemical characteristics of the particular active agent selected for use. Pharmaceutically acceptable excipients include, but are not limited to, polymers, resins, plasticizers, fillers, lubricants, diluents, binders, disintegrants, solvents, cosolvents, buffer systems, surfactants, preservatives, sweeteners, flavoring agents, pharmaceutical grade dyes or pigments, and viscosity increasing agents.

A "therapeutically effective amount" is defined herein with respect to the treatment of cancer, which is an amount that reduces, inhibits, or otherwise eliminates the growth of cancer cells or tumors. In some embodiments, the therapeutic agent may be delivered locally to a specific affected area or areas of the subject's body. In some embodiments, where such treatment is deemed more appropriate, the therapeutic agent may be administered systemically. For example, the compounds may be administered orally or parenterally. In a specific embodiment, the therapeutic agent is delivered intravenously.

As used herein, the terms "treat", "treating" and "treatment" refer to a method of alleviating or eliminating a disease, disorder and/or symptoms thereof in a subject.

SapC-DOPS refers to stable nanovesicles consisting of the lysosomal proteins sphingolipid activator c (SapC) that catabolizes glycosphingolipids and the phospholipid Dioleoylphosphatidylserine (DOPS) (fig. 7). SapC-DOPS is further described in U.S. patent No. 8,937,156 published on 20.1.2015, which is incorporated herein by reference in one embodiment, SapC has a protein sequence consisting of SDVYCEVCEF L vklevtk L IDNNKTEKEI L DAFDKMCSK L PKS L SEECQEVVDTYGSSI L SI LL vspaee L VCSM L H L CSG (SEQ ID NO: 1).

The term "fractionated radiation therapy" refers to radiation therapy in which the total dose of radiation is divided into a plurality of smaller doses, referred to as fractions of radiation, which are administered over a treatment period. In some embodiments, the radiation dose delivered by each fraction is lower than the dose effective to inhibit tumor growth when administered alone. In embodiments, the total dose of radiation is from about 20 to about 80 gray (Gy). In embodiments, fractionated radiation therapy includes about 20 to about 40 fractions, about 25 to about 35 or about 30 fractions. In embodiments, the radiation moiety comprises about 1 to about 10Gy, about 1 to about 15Gy, about 1 to about 12Gy, about 1 to about 10Gy, about 1 to about 8 gray, about 1 to about 5Gy, or about 1 to about 2 Gy.

"treatment period" refers to the length of time corresponding to a treatment regimen. In some embodiments, the combination of SapC-DOPS and fractionated radiation therapy is administered over a period of days to weeks or months. In some embodiments, the treatment period comprises a continuous period of about 20 to about 40 days.

The present disclosure shows that co-treatment of U87-MG glioblastoma cells with fractionated radiation therapy and SapC-DOPS exhibited a synergistic antiproliferative effect compared to either treatment alone. The present disclosure demonstrates that increased surface PS elevation by radiation decreases with treatment with SapC-DOPS, and that combination therapy increases the rate of cell death of malignant solid tumors in patients.

Method of treatment

In an embodiment, there is provided a method of treating a malignant solid tumor in a patient in need thereof, the method comprising administering to the patient a combination therapy comprising: fractionated radiation therapy, wherein fractionated radiation therapy comprises a plurality of radiation fractions, each of said fractions delivering a radiation dose that is less than the dose effective to inhibit tumor growth when administered alone; and a therapeutically effective amount of SapC and dioleoylphosphatidylserine (SapC-DOPS).

In another embodiment, there is provided a method of enhancing the anti-tumor efficacy of SapC-DOPS in a subject having a malignant solid tumor, the method comprising: administering to the subject a therapeutically effective amount of SapC-DOPS in combination with fractionated radiation therapy, wherein the fractionated radiation therapy comprises a plurality of fractions of radiation administered over a treatment period, each of said fractions delivering a radiation dose that is less than the dose effective to inhibit tumor growth when administered alone, wherein the fractionated radiation therapy enhances the anti-tumor efficacy of SapC-DOPS.

In some embodiments, fractionated radiation therapy includes multiple fractions of radiation administered over a treatment period. In one or more embodiments, the plurality of radiating portions includes about 20 to about 40 portions. In one or more embodiments, fractionated radiation therapy includes from about 25 to about 35 fractions. In one embodiment, fractionated radiation therapy includes about 30 fractions. In one or more embodiments, each portion can include a radiation dose of about 1 gray (Gy) to about 2 Gy.

In some embodiments, fractionated radiation therapy includes a total radiation dose of about 20Gy to about 80 Gy. Since fractionated radiation therapy includes multiple radiation fractions, fractionated radiation therapy is administered over a treatment period. In some embodiments, the treatment period comprises a continuous period of about 20 to about 40 days.

In embodiments, a therapeutically effective amount of SapC-DOPS is administered in multiple doses over a treatment period. In a specific embodiment, SapC-DOPS is administered in 10-20 doses over the treatment period. In other specific embodiments, SapC-DOPS is administered in 10-15 doses over the treatment period.

Each individual dose of the multiple doses of SapC-DOPS may contain an amount of from 0.1mg/kg to 5.0mg/k of SapC. In some embodiments, a single dose comprises an amount of 0.2mg/kg to 3.0mg/kg of SapC. In other embodiments, a single dose comprises an amount of 0.3-1.2mg/kg of SapC.

In various embodiments, one or more portions are administered prior to administration of the SapC-DOPS composition. In some embodiments, one or more portions are administered after administration of the SapC-DOPS composition in one or more doses. In one or more embodiments, one or more portions are administered concurrently with the administration of the SapC-DOPS composition.

In one or more embodiments, administration of radiation therapy and administration of SapC-DOPS are accomplished in an overlapping or alternating order. For example, a portion of the radiation may be administered to the patient on day 1, followed by a portion of the radiation and a dose of SapC-DOPS on day 2. In addition, SapC-DOPS may be administered to the patient on day 1, and the radioactive fraction on days 2 and 3.

In some embodiments, a therapeutically effective amount of SapC-DOPS is administered in 10-15 doses over a 28 day period. In an exemplary schedule, a dose of SapC-DOPS was administered 5 times within the first week; 3 times in second and third weeks; and 1 time in the fourth week.

In some embodiments, SapC-DOPS is administered parenterally. In a specific embodiment, SapC-DOPS is administered to the patient by the intravenous route.

In various embodiments, the malignant solid tumor is a brain, pancreas, lung, or neuroblastoma tumor. In one or more embodiments, the brain tumor is a glioblastoma. In certain embodiments, the method ameliorates at least one symptom of glioblastoma in a mammal selected from the group consisting of mouse, rat, dog, cat, monkey, and human.

In certain embodiments, the method further comprises administering to the patient or tumor an additional anti-cancer agent selected from the group consisting of chemotherapeutic agents, cytotoxins, antimetabolites, alkylating agents, protein kinase inhibitors, anthracyclines, antibiotics, antimitotics, corticosteroids, radiopharmaceuticals, cytokines, enzymes, interferons, yunzolan intracellular glycopeptides, lentinan, cetrafoxanil, piscibacil, ubenimex, acitreonamide, thalidomide, zoledronic acid, angiostatin, aplidine, cilanserin (cilentide), combretastatin a-4, endothelitin, halofuginone, rematant, casomovab, lenalidomide (Revlimid), squalane, ukrain, Vitaxin, cisplatin, carboplatin, nedaplatin, oxaliplatin, camptothecin derivatives, compounds or chelates including radionuclides, filgrastimulin, felicidin, levovirucin, theodolizumab, TETRACETAMORTA, TETRACERTA, TETRACERTAMETRIN, TETRACETAMIN-E, TETRACETAMORTAMETA, TETRACETAMIN-E, TETRACETAMIN, TETRACETAIN, TETRACETAMIN-E, TETRACETAMIN-4, TETRACETAMIN-1, TETRACETAMIN-4, TETRACETAMIN-1, TETRACETAMIN-4, TETRACETAMIN-1, TETRACETAMIN-7, TETRACETAMIN-7, TETRACETAMIN-.

Those skilled in the art will appreciate that the dosage regimen and amounts set forth herein are exemplary and may be varied by the attending physician depending upon the age and physical condition of the subject to be treated, the severity of the disease, the duration of the treatment, the nature of the concomitant therapy, the particular combination of therapeutic agents employed, the particular pharmaceutically acceptable excipients employed, and like factors within the knowledge and expertise of the attending physician.